logo
Frank's Team Shows They Care During His Time of Need

Frank's Team Shows They Care During His Time of Need

Associated Press18 hours ago
Frank's teammates really stepped up during his time of need and showed they genuinely care about him. That's the DaVita Difference.
About DaVita Inc.DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of March 31, 2025, DaVita served approximately 282,000 patients at 3,173 outpatient dialysis centers, of which 2,661 centers were located in the United States and 512 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
Visit 3BL Media to see more multimedia and stories from DaVita
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Versailles Hospital Center adopts digital pathology platform
Versailles Hospital Center adopts digital pathology platform

Yahoo

time27 minutes ago

  • Yahoo

Versailles Hospital Center adopts digital pathology platform

The Versailles Hospital Center has begun a digital pathology transformation by selecting Tribun Health's CaloPix imaging platform. This move is a significant step in modernising the French public healthcare system's diagnostic services and integrating artificial intelligence (AI) into pathology. The implementation of CaloPix within the pathology department is set to streamline primary diagnostics and interdisciplinary collaboration. Tribun Health CEO Jean-François POMEROL said: 'This choice reflects a shared commitment to innovating for more effective, collaborative, and patient-centered healthcare.' Tribun Health's platform has a user-friendly interface and flexibility, catering to the dynamic requirements of hospital infrastructures. It is designed to be open and interoperable, allowing it to integrate with the hospital's digital strategy. This initiative is in line with the Versailles Hospital Center and GHT 78 Sud's digital objectives, which are coordinated with GHT Nord. It contributes to a national effort to upgrade and digitise healthcare facilities. Versailles Hospital Center is GHT 78 Sud's supporting institution. Versailles Hospital Center Pathology Department head Dr Claire GLASER said: 'The selection of CaloPix is fully aligned with our digital transformation strategy. We were impressed by the solution's user-friendliness, performance, and the quality of support offered by Tribun Health's teams. 'This project, developed in collaboration with the GHT Yvelines Nord, marks a key step for the future of our specialty in the region, particularly regarding AI and collaborative work. It also enhances our integration into APHP's expert networks equipped with the same software.' Tribun Health uses data-driven technology and AI to improve precision and minimise turnaround times to assist laboratories and hospitals in transitioning from glass slide pathology to complete digital solutions. "Versailles Hospital Center adopts digital pathology platform" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Modella AI and AstraZeneca link for cancer clinical development
Modella AI and AstraZeneca link for cancer clinical development

Yahoo

time27 minutes ago

  • Yahoo

Modella AI and AstraZeneca link for cancer clinical development

Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca access to Modella AI's multi-modal foundation models. The agreement will enable the use of Modella AI's latest models, with rich feature extraction from different types of data, to speed up clinical development across AstraZeneca's worldwide oncology portfolio. AstraZeneca oncology research and development (R&D) chief AI and data scientist Jorge Reis-Filho stated: 'At AstraZeneca, AI is integrated across every aspect of clinical development. 'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.' AstraZeneca will use Modella AI's platform for cancer research R&D capabilities to improve biomarker discovery and clinical development while enhancing patient outcomes. By integrating these advanced foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods with increased speed. Modella AI CEO Jill Stefanelli stated: 'Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents. 'Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca's research engine, they will have the potential to accelerate data-driven development and enable the development of new AI agents that can automate complex R&D workflows.' In June 2025, the US Food and Drug Administration (FDA) approved AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that exhibits mutations in the epidermal growth factor receptor. "Modella AI and AstraZeneca link for cancer clinical development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Plans for new hospital in city to meet high demand
Plans for new hospital in city to meet high demand

Yahoo

time34 minutes ago

  • Yahoo

Plans for new hospital in city to meet high demand

Plans have been submitted by a developer to build a new city hospital for day patients to tackle a "continued increase" in waiting times. Thorpe Wood Hospital in Peterborough would be part of the private hospital group, Ramsay Health Care UK, which already runs the Fitzwilliam Hospital in the city. In a report submitted to Peterborough City Council, developers ELG said the project would help to manage "excessive demand in the local health system". It said the Fitzwilliam had already "reached capacity", adding: "Essential expansion is urgently required for day case and community diagnostics." It said: "This investment is seen as being important and intrinsic to reducing the continued increase in patient waiting times and deferred treatment and diagnostic services in the community." There would be on-site magnetic resonance imaging (MRI) facilities and computed tomography (CT) scanners for early diagnostic and surgical intervention. This would allow the Fitzwilliam to have more bed capacity for procedures such as complex surgeries. The new facility would be dedicated to several different areas including general surgery, ophthalmology, urology and gynaecology. The report said there was a "huge task" of clearing a backlog of NHS patients waiting for treatment, which has led to private hospitals taking on the care of some NHS patients. It is estimated 142 members of staff would work at the hospital, caring for patients coming via the private sector as well as the NHS. The single-storey hospital building is planned for a business park on the western edge of Peterborough. The plans have yet to be considered by Peterborough City Council. Follow Peterborough news on BBC Sounds, Facebook, Instagram and X. Plan to convert church hall into homes submitted Safety measures to be introduced at busy junction Former reptile pet shop to become pizza takeaway Peterborough City Council Planning Register

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store